Abstract
Nucleotide metabolism is the target of a large number of anticancer drugs including antimetabolites and specific enzyme inhibitors. We review scientific findings that over the last 10-15 years have allowed the identification of several intracellular nucleotide-degrading enzymes as cancer drug targets, and discuss further potential therapeutic applications for Rcl, SAMHD1, MTH1 and cN-II. We believe that enzymes involved in nucleotide metabolism represent potent alternatives to conventional cancer chemotherapy targets.
Keywords:
MTH1; Nucleotides; Rcl; SAMHD1; cN-II.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
5'-Nucleotidase / antagonists & inhibitors
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
DNA Repair Enzymes / antagonists & inhibitors
-
Drug Discovery / methods*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Molecular Targeted Therapy
-
Monomeric GTP-Binding Proteins / antagonists & inhibitors
-
N-Glycosyl Hydrolases / antagonists & inhibitors
-
Neoplasms* / drug therapy
-
Neoplasms* / enzymology
-
Nuclear Proteins / antagonists & inhibitors
-
Nucleotides / metabolism*
-
Phosphoric Monoester Hydrolases / antagonists & inhibitors
-
Proto-Oncogene Proteins / antagonists & inhibitors
-
SAM Domain and HD Domain-Containing Protein 1
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Nuclear Proteins
-
Nucleotides
-
Proto-Oncogene Proteins
-
Phosphoric Monoester Hydrolases
-
5'-Nucleotidase
-
NT5C2 protein, human
-
SAM Domain and HD Domain-Containing Protein 1
-
SAMHD1 protein, human
-
DNPH1 protein, human
-
N-Glycosyl Hydrolases
-
8-oxodGTPase
-
Monomeric GTP-Binding Proteins
-
DNA Repair Enzymes